Here’s What Hedge Funds Think About NovoCure Limited (NVCR)

In This Article:

We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat the S&P 500 ETFs by 14 percentage points. Investing in index funds guarantees you average returns, not superior returns. We are looking to generate superior returns for our readers. That's why we believe it isn't a waste of time to check out hedge fund sentiment before you invest in a stock like NovoCure Limited (NASDAQ:NVCR).

NovoCure Limited (NASDAQ:NVCR) shares haven't seen a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged. The stock was in 22 hedge funds' portfolios at the end of September. At the end of this article we will also compare NVCR to other stocks including 58.com Inc (NYSE:WUBA), Sociedad Quimica y Minera de Chile S.A. (NYSE:SQM), and Elbit Systems Ltd. (NASDAQ:ESLT) to get a better sense of its popularity.

5 Most Popular Stocks Among Hedge Funds
5 Most Popular Stocks Among Hedge Funds

Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

According to most traders, hedge funds are perceived as underperforming, outdated financial vehicles of the past. While there are greater than 8000 funds with their doors open today, Our researchers choose to focus on the crème de la crème of this group, around 750 funds. These investment experts preside over the lion's share of all hedge funds' total asset base, and by watching their top stock picks, Insider Monkey has uncovered various investment strategies that have historically defeated Mr. Market. Insider Monkey's flagship short hedge fund strategy surpassed the S&P 500 short ETFs by around 20 percentage points annually since its inception in May 2014. Our portfolio of short stocks lost 27.8% since February 2017 (through November 21st) even though the market was up more than 39% during the same period. We just shared a list of 7 short targets in our latest quarterly update .

[caption id="attachment_673876" align="aligncenter" width="1613"]

John Overdeck of Two Sigma
John Overdeck of Two Sigma

John Overdeck of Two Sigma Advisors[/caption]

Unlike the largest US hedge funds that are convinced Dow will soar past 40,000 or the world's most bearish hedge fund that's more convinced than ever that a crash is coming, our long-short investment strategy doesn't rely on bull or bear markets to deliver double digit returns. We only rely on the best performing hedge funds' buy/sell signals. Let's take a peek at the latest hedge fund action encompassing NovoCure Limited (NASDAQ:NVCR).